Study of a new allergy medicine for children with severe symptoms
Treatments studied
Part of Immune system & allergy clinical trials.
This study tests a new medicine called DEP114 for children aged 6 to 12 who have severe symptoms from persistent allergic rhinitis (year-round allergies). The medicine may help reduce nasal congestion and other allergy symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child must be between 6 and 12 years old.
- Your child must have a diagnosis of persistent allergic rhinitis (year-round allergies) with a severe flare-up.
- Your child must have a positive allergy test (skin prick test or blood test) to airborne allergens.
- Your child must have a nasal congestion score of at least 2 and a total nasal symptom score of at least 8.
- Your child must not have used certain steroid medicines or decongestants recently, and must not be on allergy shots.
- Your child must not have other nasal conditions, uncontrolled asthma, or certain other health issues.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine for children with moderate to severe allergic rhinitis (a condition that causes a stuffy, runny, or itchy nose). It aims to see if the new medicine is safe and effective in reducing these symptoms compared to current treatments.
This trial tests a new medicine called DW1807 for people who have both year-round allergies (like dust mites or pet dander) and asthma. It aims to see if it helps control nasal symptoms and is safe to use.
This trial compares two add-on medicines (an antihistamine and an antileukotriene) when used with a standard nasal steroid spray to see which works better at controlling allergy symptoms. If you have moderate to severe hay fever and are not currently on allergy medication, this study may help you find a more effective treatment.
This study tests an investigational injection (called JYB1904) to see if it helps reduce allergy symptoms from dust mites, pet dander, and other indoor allergens. It is for adults with moderate to severe allergic rhinitis (hay fever) who still have symptoms despite using a daily nasal steroid spray.
This study tests a new nasal spray (ALDP001) in adults with seasonal allergies to ragweed. It aims to find the best dose and how often to use it.
This trial tests if a new medicine, depemokimab, can help children aged 6 to 11 whose asthma is not well controlled with their current inhalers and who have a type of inflammation called eosinophilic asthma. It may reduce asthma attacks and improve symptoms.
Hear when a new Persistent Allergic Rhinitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.